A 20-year-old female presented with a history of psoriasis and psoriatic arthritis since childhood. She started treatment with etanercept (Enbrel ®) 1 month previously. One day after a subcutaneous ...
The safety of etanercept in this patient population was established through multiple pediatric trials, including a clinical study in 69 children aged 2 to 17 years with moderately to severely active ...
Lupin is introducing Rymti, its first biosimilar in Canada, through its partner Sandoz Canada (Sandoz). Rymti is indicated for the treatment of moderate to severe active rheumatoid arthritis, juvenile ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results